Form 425 Cyclo Therapeutics, Inc. Filed by: Cyclo Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
August 26, 2024 5:03 AM EDTAscendiant Capital analyst Lucas Ward lowered the price target on Cyclo Therapeutics (NASDAQ: CYTH) to $0.95 (from $2.60) while maintaining a Buy rating.
The analyst comments "Company completes enrollment in phase 3 trial, affirms regulatory timeline: On May 30, the company announced it has completed enrollment for its... More
